Twist Bioscience CEO Emily Leproust Reports Routine & Tax-Related Share Sales

Executive Summary

On October 5, 2026, Twist Bioscience Corp ($TWST) Chief Executive Officer Emily M. Leproust reported the disposition of 46,391 shares of common stock for total gross proceeds of approximately $8.77 million between October 1 and October 2, 2026.

Transaction Breakdown

1. October 1, 2026 (Rule 10b5-1 Sale):

   • Shares Sold: 655
   • Price per Share: $200.00
   • Proceeds: $131,000.00
   • Note: Executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on June 15, 2026.

2. October 2, 2026 (Sell-to-Cover Sale):

   • Shares Sold: 45,736
   • Price per Share: $188.884
   • Proceeds: ~$8,638,797.74
   • Note: Mandatory sell-to-cover transaction required under the company's equity incentive plans to fund tax withholding obligations triggered by RSU vesting. This was non-discretionary.

Ownership Impact

• Post-Transaction Holdings: 567,308 shares of common stock held directly.
• Derivative Holdings Unchanged: Option positions totaling 196,240 shares (131,290 options exercisable at $23.33 and 64,950 performance-based options exercisable at $67.85) remain unexercised.

Market Interpretation

The trading significance is rated Low. Over 98% of the shares sold (45,736 shares) were part of an automated sell-to-cover mechanism to satisfy statutory tax obligations tied to vesting RSUs, rather than an active portfolio rebalancing or sentiment-driven open market sale. The remaining 655 shares were liquidated via a pre-established Rule 10b5-1 plan.